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ABSTRACT
We evaluated tacrolimus/mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis
after a nonmyeloablative stem cell transplantation (NST) from a matched sibling donor (MSD). Thirty-two
patients (median age, 57 years) with advanced hematologic malignancies, who were poor candidates for a
conventional myeloablative transplantation, received fludarabine (30 mg/m2, day 4 to day 2), total-body
irradiation (TBI) (200 cGy, day 0), infusion of donor peripheral blood progenitor cells (day 0), oral tacrolimus
0.06 mg/kg twice daily (from day 3), and oral MMF at 15 mg/kg twice daily (days 0-27). Tacrolimus was
tapered from day 100 to day 180 in those patients with indolent malignancies (n  25), and from day 35
to day 56 in those with aggressive tumors (n  7). Regimen toxicities and myelosuppression were mild,
allowing 75% of patients to have entirely outpatient transplantations. One patient (3%) experienced a nonfatal
graft rejection. Rates of grades II-IV and III-IV acute GVHD were 15.6% and 3%, respectively. Acute GVHD
was diagnosed at median day 78 (range, days 31-84). Extensive chronic GVHD was observed in 10 of 24
evaluable patients (41.6%) at a median onset of day 198 (range, days 128-277), either spontaneously (n 
5) or elicited after tumor progression (n  5). Five patients experienced transplantation-related mortality
(TRM) (15.6%) from either acute GVHD-related multiorgan failure (MOF) (n 3) or infectious complications
(n 2). At median follow-up of 19 months (range, 2-41 months), the overall survival, progression-free survival,
and disease-free survival rates are 62.5%, 50%, and 40%, respectively. In conclusion, the use of tacrolimus/
MMF after MSD NST is associated with encouraging rates of GVHD control.
© 2006 American Society for Blood and Marrow Transplantation
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Nonmyeloablative allogeneic stem cell transplanta-
ion (NST) has emerged as a less-toxic alternative to
ully myeloablative allogeneic stem cell transplantation
SCT). NST derives its antitumor effect largely from the
nduction of an immune graft-versus-tumor (GVT) ef-
ect. The use of lower doses of chemotherapy and radio- o
B & M Therapy has substantially decreased TRM, allowing the
nclusion of poor candidates for myeloablative SCT,
uch as patients with advanced age, major comorbidities,
r previous myeloablative SCT.
Several groups have developed different NST ap-
roaches with varying intensities [1-7]. Low-dose total
ody irradiation (TBI) (200 cGy) is at the lowest end
f the intensity spectrum among NST conditioning
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2egimens. Investigators at Seattle tested this approach
n 45 patients who received a NST from a matched
ibling donor (MSD) and reported rates of 47% stage
I-IV acute GVHD, 70% chronic GVHD, 20% graft
ejection, and 7% TRM, using cyclosporine/MMF as
osttransplantation immunosuppression [7]. In a sub-
equent study in MUD NST recipients, the addition
f ﬂudarabine (30 mg/m2  3 days) to TBI as part of
he conditioning regimen, appeared to decrease graft
ejection [8].
This NST approach has decreased TRM both
or MSD [9] and MUD [10] recipients, due largely
o a major decrease in regimen-related direct organ
amage. In contrast, age-matched comparisons with
yeloablative SCT have shown little change in the
ncidence of GVHD after NST using cyclosporine/
MF [11].
In recent years, tacrolimus has emerged as an
lternative to cyclosporine for GVHD prevention af-
er myeloablative SCT. Both drugs are calcineurin
lockers, and tacrolimus exerts an in vitro immuno-
uppressive effect that is 100 times more potent than
hat of cyclosporine [12]. Randomized trials have
hown that posttransplantation tacrolimus/methotrex-
te is associated with decreased acute GVHD com-
ared with cyclosporine/methotrexate in patients re-
eiving a MSD [13] or matched unrelated donor
MUD) SCT [14]. We hypothesized that tacrolimus/
MF would provide superior GVHD protection after
ST than cyclosporine/MMF. Both tacrolimus and
MF are synergistic in preclinical models [15]. In
ddition, tacrolimus does not appear to interact ad-
ersely with the metabolism of MMF, whereas cyclo-
porine causes a decrease in the trough levels of its
ctive metabolite, mycophenolic acid [16-18].
Here we report the results of a prospective pilot
rial evaluating the use of tacrolimus/MMF as GVHD
revention after ﬂudarabine/TBI conditioning and a
SD NST in patients with hematologic malignancies
ho were ineligible for a conventional myeloablative
llograft. The goal was to obtain preliminary data on
he effect of substituting tacrolimus for cyclosporine
ithin the framework of the NST approach developed
y the Seattle investigators. Other components of this
ransplantation method remained intact, including the
retransplantation conditioning and collection of do-
or PBSC, and durations of postgrafting immunosup-
ression were consistent with those being tested by
he Seattle group.
ATIENTS AND METHODS
tudy Design
This prospective study was designed to test the
afety and feasibility of tacrolimus and MMF as post-
ransplantation immunosuppression in patients with d
18ematologic malignancies receiving a MSD NST after
udarabine/TBI. The study protocol was approved by
he University of Colorado Cancer Center Protocol
eview Committee and Institutional Review Board,
nd the Ethic Committees at Christchurch and Auck-
and Hospitals (New Zealand). The endpoints of the
tudy were to determine whether stable allogeneic
ematopoietic engraftment could be safely established
n these patients, and to evaluate the incidence of
rade II-IV GVHD associated with this treatment.
The inclusion criteria were the following: (1)
vailability of a donor, either an HLA-identical sibling
r a phenotypically matched family member, and (2)
atients with hematologic malignancies not eligible
or a myeloablative allogeneic or autologous trans-
lantation on the following grounds: (a) age 50 with
ML or ALL, in  second complete remission (CR2)
r with 10% blasts in bone marrow; (b) age 50
ith high-grade MDS; (c) age 50 with CML after
ailure of imatinib; (d) age 50 years with HD, NHL,
r myeloma, after failure of chemotherapy and not
andidates for an autologous transplantation; (e) any
ge with the foregoing malignancies, after failure of a
revious autologous SCT; or (f) any age with major
edical or psychiatric comorbidities considered inel-
gible for a myeloablative SCT. Patients with CLL
nd low-grade NHL were required to have failed at
east treatment with a purine analogue and anti-CD20
onoclonal antibody rituximab.
Speciﬁc exclusion criteria were (1) myeloma, NHL,
r HD eligible for an autologous SCT; (2) age 50
ligible for myeloablative allogeneic SCT; (3) rapidly
rogressive aggressive NHL; (4) active uncontrolled
NS involvement with malignancy; (5) fertile men or
omen unwilling to use contraceptive techniques dur-
ng and for 12 months after treatment; (6) pregnancy;
7) HIV positivity; or (8) severe organ dysfunction,
ndicated by (a) left ventricle ejection fraction 35%,
b) carbon monoxide diffusion capacity (DLCO)
35% of predicted or receiving supplementary con-
inuous oxygen; (c) total bilirubin 2  the upper
imit of normal and/or transaminases 4  the upper
imit of normal; (d) Karnofsky score 50 for patients
65 years, or 70 for patients age 65; or (e) hyper-
ension poorly controlled on antihypertensive ther-
py. Patients with renal failure were considered eligi-
le, although those with serum creatinine 2 mg/dL
ere informed that they could possibly require hemo-
ialysis during the course of the study.
tudy Therapy
Treatment was initiated on an outpatient basis,
ith patients only admitted as medically necessary for
ontrol of transplantation complications. Patients
ere conditioned with ﬂudarabine (30 mg/m2/day on
ays 4 to 2) and TBI at 200 cGy on day 0, at 6-7
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BGy/min from a linear accelerator, followed by stem
ell infusion on day 0. The source of stem cells was
onor peripheral blood progenitor cells (PBPC) mo-
ilized with granulocyte colony-stimulating factor (G-
SF) at 16 g/kg/day for 5 days, with apheresis prod-
cts collected on the ﬁfth day. Oral tacrolimus was
tarted on day 3 at 0.06 mg/kg twice daily, and oral
MF was initiated at 15 mg/kg twice daily from day
(afternoon dose only).
Therapeutic monitoring of tacrolimus, with mea-
urement of whole blood trough levels at least once a
eek, targeted 10-20 ng/mL. Holding of tacrolimus
osing and/or 25% dose reductions were made in the
resence of tacrolimus toxicity, or with levels 20
g/mL in the absence of toxicity. Blood pressure,
enal function tests, electrolytes, and magnesium were
onitored at least 3 times per week while receiving
acrolimus at full dose, and then at least once weekly
ntil discontinuation of tacrolimus.
Dose adjustments of MMF for gastrointestinal
oxicity deemed related to this drug mandated a 20%
ose reduction, with a further 20% reduction in the
bsence of improvement. Severe MMF-related gastro-
ntestinal toxicity required discontinuation of this
rug. Dose adjustments were not contemplated for
ematopoietic toxicity, except for severe and persis-
ent (100 neutrophils/mm3 for 5 days) or late (af-
er day 21) neutropenia.
In the event of nausea and/or vomiting preventing
ral intake at any time during tacrolimus or MMF
reatment, these drugs were administered through an
ntravenous (IV) route, using IV-to-oral conversion
atios of 1 to 4 and 1 to 1, respectively.
MMF was discontinued without tapering after the
econd dose on day 27. Patients received tacrolimus
ccording to 2 immunosuppressive schedules. Those
ith indolent diseases (cohort A) initiated tacrolimus
apering, in the absence of GVHD, on day 100 by
pproximately 10% per week through day 180. Co-
ort A included patients with CML in ﬁrst chronic
hase, CLL, low-grade NHL, myeloma, and MDS
ith 5% marrow blasts. Those patients with aggres-
ive malignancies (cohort B) initiated tacrolimus ta-
ering, in the absence of GVHD, on day 35 by
pproximately 33% per week, to be stopped by day
56. Cohort B included intermediate- and high-grade
HL, HD, AML, ALL, CML beyond the ﬁrst
hronic phase, and refractory anemia with excess of
lasts (RAEB).
VHD Grading and Treatment
Diagnosis and clinical grading of acute and chronic
VHD were made based on established criteria
19,20]. Treatment decisions were based on each at-
ending physician’s assessment of the severity of acute
VHD and usually included initially 6-methyl-pred- G
B & M Tisolone or prednisone at 1-2 mg/kg/day, with taper-
ng after 14 days. Extensive chronic GVHD was usu-
lly treated with prednisolone and tacrolimus. Cases
f serious acute or chronic GVHD were retrospec-
ively identiﬁed following the criteria recently deﬁned
y Flowers et al.[21]: (1) death related to GVHD or its
reatment, (2) severe disability due to GVHD or its
reatment, (3) 3 or more major infections (eg, sepsis,
neumonia, mold infections, central nervous system
nfections) within 1 year because of GVHD, (4) hos-
italization for 60 days in a single year because of
VHD, or (5) suicide or hospitalization because of
VHD or its treatment.
valuation of Chimerism
Chimerism studies, using short-tandem repeat or
uorescent in situ hybridization analyses for sex-
atched and sex-mismatched transplantations, re-
pectively, were to be performed at 1, 2, 3, and 12
onths posttransplantation in the blood CD3 com-
artment and bone marrow. Mixed chimerism was
eﬁned as the detection of donor T cells at between
% and 95% of the total T-cell population; donor
himerism was deﬁned as detection of donor T cells at
95% of the total T cells. Failure of engraftment was
eﬁned as the absence of detectable donor cells in the
arrow and peripheral blood on day 56.
onor Lymphocyte Infusions
On discontinuation of immunosuppression, donor
ymphocyte infusions (DLIs) were considered for
hose patients without GVHD who presented with
ersistent disease and/or stable mixed chimerism. Pa-
ients without detectable donor engraftment were not
ffered DLI. If rapid disease progression occurred
arly posttransplantation, then the patient was consid-
red a study treatment failure and offered alternative
reatments failure at the discretion of the treating
hysician, with or without DLI off protocol.
The ﬁrst DLI consisted of 1  106 unirradiated
onor T cells/kg. In the event of no GVHD, persis-
ent disease, and failure to either achieve full donor
himerism or to exhibit an increase in donor T-cell
himerism 20% after the ﬁrst DLI, each patient
ould receive up to 4 DLIs at increasing (1/2 log) cell
oses, administered more than 28 days apart (if PD) or
5 days apart (if SD). Patients who developed grade
GVHD after a DLI were excluded from receiving
urther DLI on this protocol.
upportive Care
Posttransplantation growth factors were not given
nless severe neutropenia (ANC 100) developed or
ersisted past day 27. Patients with active uncon-
rolled bacterial or fungal infections could receive
-CSF for neutropenia 500/L.
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2Patients received prophylaxis for Pneumocystis ca-
inii, Herpes, Candida, and cytomegalovirus (CMV)
ollowing common guidelines [22]. Speciﬁcally, oral
uconazole was administered from day 0 to day 75
t 400 mg/day for creatinine clearance (CrCl) 50
L/min, at 200 mg/day for CrCl 11-50 mL/min, or
00 mg 3 times weekly for CrCl 11 mL/min. CMV
onitoring, with preemptive treatment if necessary,
as performed in cases of seropositive donor and/or
ecipient, using a DNA hybrid capture assay, com-
encing on day 14 and repeated weekly until day
100.
Routine antibacterial prophylaxis was not used un-
ess neutropenia (ANC 500/L) developed, in which
ase levoﬂoxacin therapy was administered until neu-
ropenia resolved. Neutropenic fevers were treated
ith standard antibiotics, avoiding aminoglycosides.
tatistical Analysis
The minimum target enrollment was established
t 30 patients. A 2- or 3-stage stopping rule was
nstituted for excessive transplantation-related mortal-
ty (TRM) within the ﬁrst 100 days. Fifteen patients
ere to be enrolled in the ﬁrst stage of the trial. If 4 or
ore patients experienced TRM, then the trial would
e stopped, concluding that early TRM exceeded 5%.
f 3 or fewer patients experienced TRM, then 15
dditional patients were to be enrolled.
The 95% conﬁdence interval (CI) of the incidence
f GVHD was estimated using the exact binomial dis-
ribution. Survival analyses used the Kaplan-Meier
ethod [23]. Progression-free survival (PFS) was de-
ned as the time from study entry to a documented
elapse or progression, or death without relapse or pro-
ression. Overall survival (OS) was deﬁned as the time
rom study entry to death from any cause. The statistical
nalyses were performed using the Number Cruncher
tatistical System (2001, NCSS, Kaysville, UT).
ESULTS
atient Characteristics
A total of 32 patients with hematologic malignan-
ies were prospectively enrolled in this study at the
niversity of Colorado (n  17), Christchurch Hos-
ital (n 12), and Auckland Hospital (n 3) between
001 and 2004 (Table 1). The median patient age was
7 years (range, 36-68 years). The patients had un-
ergone extensive previous treatments (a median of 3
ourses of previous therapy), including previous au-
ologous transplantation in 16 patients. Two patients
ad previously untreated disease (MDS), 7 patients
nderwent transplantation with progressive disease
3 NHL, 2 MDS, 1 AML, 1 HD, 1 myeloma), and 23
atients had tumors either stable or in response to
revious treatments. p
20Twenty-ﬁve patients with indolent malignancies
ere allocated to cohort A (long tacrolimus taper), and
patients with aggressive disease were enrolled in
ohort B (short tacrolimus taper).
urvival and Outcome
At median follow-up of 19 months (range, 2-41
onths), 20 patients (62.5%) were alive. Of these
atients, 16 (50%) were free of progression, and 13
40.6%) were in CR. Four patients were alive with PD
ost-NST. Median EFS was 23 months; median OS
as not reached (Fig. 1).
TRM occurred in 5 patients (15.6%) (Fig. 2).
hree patients died from multiorgan failure related to
VHD (on days 105, 343, and 354), and 2 died
rom infectious complications probably related to
VHD treatment (on days 141 and 625). Six pa-
ients died from tumor progression. One additional
able 1. Patient Demographics (n  32)
ge, median (range) (years) 57 (36-68)
ex, no. (%)
Male 21 (66)
Female 11 (34)
ndication of nonmyeloablative transplantation,
no. (%)
Age >50 years 26 (81)
Substantial comorbidities 8 (25)
Previous myeloablative transplant 16 (50)
iagnosis, no. (%)
Non-Hodgkin’s lymphoma 12 (37)
Follicular lymphoma 7 (22)
Transformed follicular lymphoma 2 (6)
Diffuse large-cell lymphoma 1 (3)
Mantle-cell lymphoma 1 (3)
NK lymphoma 1 (3)
Myeloma 12 (37)
Myelodysplastic syndrome 5 (16)
Acute myeloblastic leukemia, CR >2 2 (6)
Hodgkin’s disease 1 (3)
isease status at transplant, no. (%)
CR 1 2 (6)
CR >2 6 (19)
Partial remission >2 5 (16)
Plateau phase (MM) 9 (28)
Stable disease 1 (3)
Progressive disease 7 (22)
Untreated 2 (6)
umber of previous lines of treatment,
median (range) 3 (1-7)
onor, no. (%)
6/6 HLA-matched sibling 31 (97)
6/6 HLA-matched son 1 (3)
onor sex, no. (%)
Male 15 (47)
Female 17 (53)
raft, no. (%)
Peripheral blood 31 (97)
Bone marrow 1 (3)
MV serologic status, no. (%)
Donor, recipient, or both seropositive 27 (84)
Donor and recipient seronegative 5 (16)atient died (on day 981) from aspiration pneumo-
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Bia related to mediastinal radiotherapy for a second
rimary adenocarcinoma of the lung, while in CR of
is original transformed NHL.
VHD
Four patients had grade II acute GHVD, and 1
atient had grade IV acute GVHD. The incidence of
rade II-IV acute GHVD was 15.6% and that of grade
II-IV acute GVHD was 3%, involving the skin (n 
), gut (n  2), and liver (n  1), and presenting at
edian day71 (range, days31-84) (Fig. 3). Only
patients (6.25%) presented with acute GVHD (both
rade II) while still receiving tacrolimus therapy. The
ncidence of grade II-IV acute GVHD was 12% in
ohort A and 28% in cohort B 28% (P  not signif-
cant [NS]). One other patient had grade I GVHD of
he skin.
Three patients experienced resolution of GVHD
nd are currently alive and free of disease. The other
Figure 1. Overall survival (OS)Figure 2. Nonrelapse mortality and mo
B & M Tpatients died, 1 from acute GVHD-associated mul-
iorgan failure (MOF), 1 from invasive pulmonary
spergillosis after steroid therapy, and 1 from PD after
esolution of GVHD.
Extensive chronic GVHD was observed in 10 of
4 evaluable patients (41.6%), appearing spontane-
usly in 5 of these (20.8%) at median day 240
range, day 151-277), or elicited after PD by im-
unosuppression withdrawal (n  4) or DLI (n  1)
Fig. 4). It involved the skin in 7 patients, gut in 7,
iver in 6, lungs in 1, mouth in 2, and eyes in 1. There
as 1 additional case of limited GVHD of the mouth.
Five of these patients experienced resolution of
heir GVHD and were tapered off immunosuppres-
ants, whereas 1 patient was still receiving treatment
n day 399. Five patients died, 1 from PD, 1 from
verwhelming sepsis while on immunosuppression, 2
rom GVHD-related MOF, and 1 from complications
f treatment for a second primary tumor after resolu-
ent-free survival (EFS) curves.rtality from disease progression.
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2ion of his chronic GVHD (described earlier). The
ncidence of extensive chronic GVHD among evalu-
ble patients was 41% in cohort A and 20% in cohort
(P  NS).
In 3 cases, the picture of chronic GVHD was
onﬁbrotic changes consistent with the recently de-
cribed syndrome of “late-onset acute GVHD” [10].
ne of these patients had involvement of the skin and
ut starting spontaneously on day 220; 1 had
VHD of the skin, gut, and liver on day 220 that
as elicited by immunosuppression withdrawal; and 1
ad involvement of the skin and liver on day 323
fter DLI.
Seven cases of “serious GVHD” (21.8%), as de-
ned recently [18], were identiﬁed. Five of these pa-
Figure 3. CumulativeFigure 4. Cumulative inciden
22ients died from complications of GVHD (n  3) or
ts treatment (n  2), 1 patient experienced disability
nd 1 patient had prolonged hospitalization caused by
xtensive chronic GVHD.
acrolimus-Related Toxicity
Other toxicities related to tacrolimus included re-
al failure, which was grade 1 in 1 patient, grade 2 in
patients, grade 3 in 4 patients, and grade 4 requiring
ransient hemodyalisis in 1 patient. Seven patients
omplained of mild to moderate headache, 2 patients
omplained of mild tremors, and 2 patients had grade
hemolysis. Two patients experienced acute pancre-
titis that resolved; in 1 case it was attributed to
nce of acute GVHD.ce of chronic GVHD.
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Bacrolimus, whereas in the other case the picture ap-
eared weeks after tacrolimus discontinuation and ap-
eared to be related to alcohol. One patient experi-
nced grade 1 peripheral neuropathy.
Overall, 24 patients experienced some degree of
ausea or emesis in the ﬁrst few weeks of tacrolimus
herapy. Nausea was grade 1 in 19 patients (with no
omiting in 14), grade 2 in 4 patients (with some
omiting in 3), and grade 3 with vomiting in 1 patient.
In addition, 3 patients experienced grade 3 hyper-
lycemia caused by steroids prescribed for GVHD.
wo patients had steroid-induced mental status changes,
rade 2 in one and grade 4 with severe confusion in the
ther.
nfectious Complications
Fourteen patients (44%) presented with at least 1
nfectious episode. Two patients experienced fatal in-
ections while receiving treatment for GVHD: mixed
acterial (methicillin-resistant Staphylococcus aureus) and
spergillus pneumonia in 1 case and overwhelming
epsis caused by an unidentiﬁed microorganism in 1
ase. In addition, the following infections were ob-
erved, which resolved: CMV colitis (n  3), herpes
oster (n  2), gastrointestinal herpes simplex virus
HSV) (n  1), genital HSV (n  1), bacterial otitis
edia (n  2), hepatitis B reactivation (n  1), and
est Nile virus (n  1). CMV viremia without end-
rgan disease was detected in 3 patients.
himerism Analyses
One patient, with previously untreated RAEB, ex-
erienced graft rejection. She died from PD on day
185 (Table 2). The remaining 31 patients had sus-
ained allografts, with full donor chimerisms by 1 year
ost-NST in 80% of them.
mmunosuppression Withdrawal and Donor
ymphocyte Infusions
Thirteen patients underwent immunosuppression
ithdrawal for PD. Five patients subsequently devel-
ped extensive chronic GVHD; 3 of them (with trans-
ormed NHL, NK NHL, and RAEB, respectively)
xperienced a CR, whereas the other 2, both with
yeloma, did not respond. Of the 8 patients who did
ot develop GVHD, there was 1 CR in a myeloma
able 2. Chimerism Analyses
1 Mon
edian % (range) of donor cells
T cells 88 (30-9
Bone marrow 95 (14-1
himerism
Percentage of patients with mixed chimerism 77%
Percentage of patients with donor chimerism 23%
B & M Tase, whereas none of the remaining 7 patients re-
ponded.
Six patients received 1 (n 3), 3 (n 1), or 4 (n 2)
oses of DLI with no preceding salvage chemother-
py. All 6 of these patients had full donor chimerism
efore DLI. One of them, who initially experienced a
R of his transformed NHL, subsequently developed
evere GVHD and died from MOF. None of the
ther 5 patients receiving DLI (1 with follicular NHL,
with myeloma, and 2 with advanced MDS) responded.
One patient received a second NST from a differ-
nt donor for progressive RAEB and is currently in
R 4 months after the second transplantation.
ISCUSSION
Fludarabine/low-dose TBI has emerged as an im-
ortant relatively nontoxic preparative regimen for
llogeneic transplantation, suitable for older patients
nd those with relative contraindications to conven-
ional allografting. In trials reported by the Seattle-
ased multicenter consortium, prevention of GVHD
nd graft rejection has relied on cyclosporin/MMF, an
pproach that represents a translation of canine pre-
linical studies.
Because the major morbidity and treatment mor-
ality with NST is related to GVHD, improved
VHD prevention could further enhance the safety of
his treatment. Furthermore, recent analyses suggest
hat acute GVHD, particularly early-onset GVHD, is
ssociated with increased TRM [24] but not with
mproved disease control, for which chronic GVHD
ppears more important [25].
This pilot phase II trial was performed to provide
reliminary data on the effect of substituting tacroli-
us/MMF for cyclosporin/MMF in patients receiving
MSD NST after ﬂudarabine/TBI. Only 2 patients
xperienced grade 4 toxicities attributable to tacroli-
us, both of which reverted: renal failure and acute
ancreatitis, the latter a rare complication of this drug
26]. Most patients experienced only mild nausea,
hich allowed good compliance with oral therapy and
chievement of therapeutic tacrolimus levels and ulti-
ately resulted in outpatient transplantation for most
atients. The incidence of CMV reactivation (16%)
nd fungal infection (3%) observed in this trial are
2 Months 3 Months 12 Months
74 (52-100) 75 (33-100) 93 (86-100)
96.5 (11-100) 95 (19-100) 98.5 (97-100)
77% 86% 20%th
7.5)
00)23% 14% 80%
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2onsistent with previously reported data in this setting
27,28].
Our preliminary observations suggest encouraging
ates of acute and chronic GVHD control and low
RM resulting from this approach. We observed a
5.6% rate of grade II-IV acute GVHD starting on
edian day 71. These observations may compare
avorably with previous results using cyclosporine/
MF reported by McSweeney et al. [7], who reported
47% incidence of acute grade II-IV GVHD, starting
t median day 40. The control of acute GVHD
rovided by tacrolimus/MMF in our trial appears en-
ouraging, with very few patients developing acute
VHD while receiving full doses of tacrolimus. This
esulted in elimination of early deaths within the ﬁrst
00 days of transplantation. The single early death on
ay105 occurred in a patient in the high-risk cohort
or whom GVHD was induced to treat persistent
isease. The ability to largely eliminate early acute
VHD with tacrolimus/MMF after ﬂudarabine/low-
ose TBI has potential implications for nonmyeloab-
ative allografting of nonmalignant disease, in which
VHD is especially counterproductive.
There was a 42% incidence of extensive chronic
VHD, half of which was purposefully elicited as
reatment for PD. In all but 1 case, chronic GVHD
resented after discontinuation of tacrolimus. Three
f these patients presented with nonﬁbrotic changes in
kin, liver, and/or gut, compatible with the recently
escribed picture of “late-onset acute GVHD” [10].
hether extended GVHD prophylaxis with tacroli-
us can reduce the later onset of GVHD seen during
r after tacrolimus tapering is an important question
o answer. Previous retrospective data from cyclospor-
ne studies [29] may not be predictive for this ques-
ion. While designing this study, we decided to adjust
he length of immunosuppression to the estimated
ndividual relapse risk, establishing a shorter (through
ay 56) tacrolimus taper for patients with rapidly
roliferating disease and a longer (through day 180)
acrolimus taper for those with indolent disease. The
mall size of the 2 cohorts does not allow for mean-
ngful comparisons of the respective incidences of
cute and chronic GVHD. It is noteworthy that the
ncidence of GVHD in both cohorts appears to com-
are favorably with previous results using cyclospor-
ne/MMF [7]. Although our study was not designed to
ormally test a risk-adjusted strategy of length of im-
unosuppression, this concept may merit further
valuation.
Our early experience with this immunosuppressive
egimen needs to be conﬁrmed in larger trials. We
ecently reported excellent rates of early GVHD pro-
ection with this immunosuppressive combination af-
er MSD [30] myeloablative SCT, suggesting that this
ombination may have broader application for MSD
ransplantations. In conclusion, our pilot trial of ta-
24rolimus/MMF in patients receiving NST from an
SD shows that this treatment is safe, permits out-
atient transplantations in most cases, and is associ-
ted with encouraging rates of acute and chronic
VHD control and excellent early survival.
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